Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Mangano and colleagues1 investigated the potential long-term effects of aprotinin use following CABG surgery. It appears that 2 important determinants of long-term CABG outcomes were not included in these analyses.
First, the extent of underlying coronary disease (1-, 2- or 3-vessel coronary disease; presence or absence of left main trunk disease) was not discussed.
Habib RH, Zacharias A, Schwann TA. Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery. JAMA. 2007;297(22):2475-2477. doi:10.1001/jama.297.22.2476-b